References
- Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–74.
- Shiffman ML. Side effects of medical therapy for chronic hepatitis C. Ann Hepatol 2004;3:5–10.
- Baynes RD, Bezwoda WR, Dajee D, Lamparelli RD, Bothwell TH. Effects of alpha-interferon on iron-related measurements in human subjects. S Afr Med J 1990;78:627–8.
- Stam TC, Swaak AJ, Kruit WH, Eggermont AM. Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b. Eur J Clin Invest 2002;32(Suppl 1):79–83.
- Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology 2011;54:328–43.
- Ferrara F, Ventura P, Vegetti A, Guido M, Abbati G, Corradini E, . Serum ferritin as a predictor of treatment outcome in patients with chronic hepatitis C. Am J Gastroenterol 2009;104:605–16.
- Emmenegger U, Schaer DJ, Larroche C, Neftel KA. Haemophagocytic syndromes in adults: current concepts and challenges ahead. Swiss Med Wkly 2005;135:299–314.
- Barut S, Dincer F, Sahin I, Ozyurt H, Akkus M, Erkorkmaz U. Increased serum ferritin levels in patients with Crimean-Congo hemorrhagic fever: can it be a new severity criterion. Int J Infect Dis 2010;14:e50–4.
- Bozdayi AM, Aslan N, Bozdayi G, Türkyilmaz AR, Sengezer T, Wend U, . Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol 2004;149: 2115–29.
- Altuglu I, Soyler I, Ozacar T, Erensoy S. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis 2008;12: 239–44.
- Aktaş E, Ogedey ED, Külah C, Beğendik Cömert F. Hepatitis C virus genotypes in a province of western Black Sea region, Turkey. Mikrobiyol Bul 2010;44:647–50.
- Price L, Kowdley KV. The role of iron in the pathophysiology and treatment of chronic hepatitis C. Can J Gastroenterol 2009;23:822–8.
- Alexander J, Kowdley KV. Effects of iron and HFE mutations on response to therapy in chronic hepatitis C: an ironic interaction? Gastroenterology 2006;131:1635–8.
- Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, . Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology 2011 Nov 16. [Epub ahead of print]
- Yada N, Kudo M, Chung H, Hayaishi S, Takita M, Ueda T, . PEG-IFNalpha/RBV combination therapy for chronic hepatitis C patients increases serum ferritin level while it improves sustained viral response rate. Intervirology 2010; 53:60–5.